NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

CPNG

Coupang Inc

Jul 03 • 04:00PM ET

30.29

Dollar change +0.26
Percentage change 0.87	%

Consumer Cyclical • Internet Retail • USA • NYSE

Peers: AMZN BABA JD SHOP EBAY PDD SE ETSY MELI W

| Held by: IWP IWF IWR VONG SPDW IWB DFAC VT FMDE FNDA

Index	-	P/E	219.02	EPS (ttm)	0.14	Insider Own	31.03%	Shs Outstand	1.65B	Perf Week	1.61%
Market Cap	54.99B	Forward P/E	42.47	EPS next Y	0.71	Insider Trans	-6.63%	Shs Float	1.25B	Perf Month	7.34%
Enterprise Value	52.90B	PEG	1.64	EPS next Q	0.07	Inst Own	53.18%	Short Float	0.96%	Perf Quarter	34.68%
Income	256.00M	P/S	1.77	EPS this Y	289.11%	Inst Trans	0.17%	Short Ratio	1.13	Perf Half Y	36.32%
Sales	31.06B	P/B	12.52	EPS next Y	129.11%	ROA	1.66%	Short Interest	11.97M	Perf YTD	37.81%
Book/sh	2.42	P/C	8.87	EPS next 5Y	133.19%	ROE	6.06%	52W High	30.91 -2.01%	Perf Year	43.69%
Cash/sh	3.41	P/FCF	55.36	EPS past 3/5Y	- -	ROIC	3.44%	52W Low	18.16 66.80%	Perf 3Y	138.50%
Dividend Est.	-	EV/EBITDA	58.78	Sales past 3/5Y	18.03% 36.99%	Gross Margin	29.30%	Volatility	2.59% 2.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.70	EPS Y/Y TTM	-80.08%	Oper. Margin	1.42%	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.90	Sales Y/Y TTM	20.88%	Profit Margin	0.82%	RSI (14)	69.66	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	1.16	EPS Q/Q	2051.85%	SMA20	4.64%	Beta	1.16	Target Price	31.45
Payout	0.00%	Debt/Eq	0.93	Sales Q/Q	11.16%	SMA50	11.36%	Rel Volume	0.63	Prev Close	30.03
Employees	95000	LT Debt/Eq	0.70	Earnings	May 06 AMC	SMA200	23.29%	Avg Volume	10.56M	Price	30.29
IPO	Mar 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.15% -1.37%	Trades		Volume	6,639,518	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-25	Upgrade	Deutsche Bank	Hold → Buy	$28.50
Oct-07-24	Upgrade	Bernstein	Underperform → Outperform	$30
Sep-04-24	Upgrade	CLSA	Hold → Outperform	$18 → $31
May-16-24	Upgrade	UBS	Neutral → Buy	$26
May-03-24	Resumed	BofA Securities	Buy	$30
Apr-15-24	Upgrade	Citigroup	Neutral → Buy	$19 → $26
Feb-29-24	Upgrade	Deutsche Bank	Hold → Buy	$18.50 → $21
Jan-16-24	Downgrade	Citigroup	Buy → Neutral	$20 → $17
Dec-20-23	Downgrade	UBS	Buy → Neutral	$26 → $18.50
Aug-09-23	Downgrade	Deutsche Bank	Buy → Hold	$20
Mar-02-23	Downgrade	BofA Securities	Buy → Neutral	$27 → $18
Mar-01-23	Upgrade	Deutsche Bank	Hold → Buy	$20
Feb-09-23	Initiated	Barclays	Overweight	$20
Dec-01-22	Initiated	New Street	Buy	$25
Oct-07-22	Initiated	HSBC Securities	Buy	$27.80
Aug-16-22	Downgrade	CLSA	Outperform → Sell	$16.40
Aug-11-22	Downgrade	Deutsche Bank	Buy → Hold	$15 → $18.50
Aug-09-22	Initiated	Macquarie	Outperform	$26
Jul-01-22	Upgrade	Credit Suisse	Neutral → Outperform	$28 → $19
Jun-29-22	Initiated	Morgan Stanley	Overweight	$18

Show Previous Ratings

Today 02:43AM	Coupang Rebrands AI Cloud Service as Coupang Intelligent Cloud/CIC, Offers GPU-as-a-Service (Insider Monkey)
Jul-03-25 09:30AM	Wall Street Bulls Look Optimistic About Coupang (CPNG): Should You Buy? (Zacks)
01:36AM	Coupang's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jul-01-25 09:00PM	Coupang Unveils Rebranding of AI Cloud Computing Service (Business Wire)
Jun-30-25 06:00PM	Coupang, Inc. (CPNG) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
09:00AM	Loading…
09:00AM	Here is What to Know Beyond Why Coupang, Inc. (CPNG) is a Trending Stock (Zacks)
Jun-26-25 02:04PM	Josh Brown's Best Stocks in the Market: Coupang (CNBC TV)
Jun-24-25 06:00PM	Coupang, Inc. (CPNG) Outpaces Stock Market Gains: What You Should Know (Zacks)
11:54AM	Coupang, Inc. (CPNG): A Bull Case Theory (Insider Monkey)
Jun-19-25 04:23AM	Farfetch Supercharges Advertising Service for Brands on the Platform (WWD)
Jun-18-25 09:00AM	Is Trending Stock Coupang, Inc. (CPNG) a Buy Now? (Zacks)
Jun-17-25 12:36AM	3 Unpopular Stocks with Questionable Fundamentals (StockStory)
Jun-11-25 07:00PM	Coupang: A Strong Contender in the E-Commerce Arena (Motley Fool)
Jun-09-25 09:30AM	Should You Invest in Coupang Right Now? (Motley Fool)
08:53AM	Why Coupang Rallied 20% in May (Motley Fool)
12:01AM	Loading…
12:01AM	Farfetch Pushes Into South Korea, One of the Worlds Biggest Luxury Markets (WWD)
Jun-07-25 05:10AM	Why Is Everyone Talking About Coupang's Stock? (Motley Fool)
Jun-06-25 09:00AM	Is Most-Watched Stock Coupang, Inc. (CPNG) Worth Betting on Now? (Zacks)
Jun-04-25 04:10AM	2 Stocks That Could Turn $1,000 Into $5,000 by 2030 (Motley Fool)
May-31-25 04:07AM	This Soaring Hypergrowth Technology Stock Still Has Plenty of Room to Run (Motley Fool)
May-28-25 09:30AM	Is It Worth Investing in Coupang (CPNG) Based on Wall Street's Bullish Views? (Zacks)
May-27-25 03:23PM	Morgan Stanley Names Coupang (CPNG) Its New Top Pick, Lifts PT (Insider Monkey)
05:45AM	2 Brilliant Growth Stocks to Buy and Hold for 20 Years (Motley Fool)
May-26-25 09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
May-25-25 04:39AM	Profit or Promise? Decoding Coupang's Global Expansion in Q1 2025 (GuruFocus.com)
May-24-25 08:00AM	3 Monster Growth Stocks That Could Soar 31% to 116%, According to Wall Street (Motley Fool)
May-22-25 11:37AM	Prediction: Coupang Will Beat the Market. Here's Why. (Motley Fool)
04:15AM	Better Growth Stock: Coupang vs. Sea Limited (Motley Fool)
May-16-25 04:12AM	1 No-Brainer Growth Stock to Buy Right Now and Hold for 10 Years (Motley Fool)
May-14-25 07:37PM	Analyst Report: Coupang, Inc. (Morningstar Research)
09:00AM	Loading…
May-13-25 09:00AM	Coupang, Inc. (CPNG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
May-09-25 08:37AM	2 Soaring Stocks That Have Room to Run (Motley Fool)
03:51AM	Coupang, Inc. (CPNG): Among Billionaire David Abrams' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 09:30AM	Is Coupang (CPNG) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
01:48AM	Why Coupang, Inc. (CPNG) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 07:17PM	Tracking Baillie Gifford's 13F Portfolio - Q1 2025 Update (Seeking Alpha) +10.83%
05:40PM	Coupang: Beginning A Monetization Cycle (Seeking Alpha)
01:21PM	Alphabet reacts to Apple, Coupang buyback, Wynn Resorts upgrade (Yahoo Finance Video)
01:11PM	Coupang: Better Than Amazon (Seeking Alpha)
12:21PM	CPNG Q1 Earnings Call: FLC Marketplace, Taiwan Expansion, and Share Buyback Program Highlight Strategy (StockStory)
10:11AM	Analyst Report: Coupang, Inc. (Morningstar Research)
08:36AM	Q1 2025 Coupang Inc Earnings Call (Thomson Reuters StreetEvents)
03:24AM	Coupang Inc (CPNG) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments (GuruFocus.com)
May-06-25 06:10PM	Coupang, Inc. (CPNG) Q1 Earnings Match Estimates (Zacks)
04:05PM	Coupang Announces Results for First Quarter 2025 (Business Wire)
May-05-25 11:22AM	Coupang, Inc. (CPNG): Among The High Growth Companies Hedge Funds Are Buying (Insider Monkey)
May-01-25 11:08AM	Coupang Gears Up to Post Q1 Earnings: What's in Store for the Stock? (Zacks)
10:00AM	Got $3,000? 2 Hypergrowth Stocks Down Over 25% to Buy and Hold for the Long Term (Motley Fool)
Apr-30-25 08:09PM	Is Coupang Inc. (NYSE:CPNG) the Best Growth Stock to Buy for the Next 3 Years? (Insider Monkey)
05:50PM	Coupang, Inc. (CPNG) Stock Declines While Market Improves: Some Information for Investors (Zacks)
10:01AM	Carvana (CVNA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-29-25 10:01AM	Coupang, Inc. (CPNG) Earnings Expected to Grow: Should You Buy? (Zacks)
03:55AM	3 Growth Stocks Down 25% or More to Buy Right Now (Motley Fool)
Apr-28-25 06:00PM	Coupang, Inc. (CPNG) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-27-25 04:32AM	Stock Market Sell-Off: 3 No-Brainer Growth Stocks to Buy Right Now (Motley Fool)
Apr-25-25 09:37AM	2 Magnificent Stocks Near 52-Week Lows (Motley Fool)
Apr-23-25 06:12PM	Jim Cramer Likes Coupang (CPNG): "It's the Amazon of South Korea" (Insider Monkey)
04:51PM	KILL Coupang Partners with the Department of Commerces International Trade Administration to Help American Businesses Sell Overseas (Business Wire)
12:10PM	Coupang, Inc. (CPNG): Among Top Stocks in Bill Gates' Portfolio with Huge Upside Potential (Insider Monkey)
09:00AM	Investors Heavily Search Coupang, Inc. (CPNG): Here is What You Need to Know (Zacks)
Apr-22-25 08:29PM	Lightning Round: Quanta Services is a buy, says Jim Cramer (CNBC TV)
04:05PM	Coupang to Announce First Quarter 2025 Results on May 6, 2025 (Business Wire)
07:00AM	Worried About a Bear Market? 3 Reasons to Buy Coupang Stock Like There's No Tomorrow. (Motley Fool)
04:36AM	Is Beaten-Down Coupang Stock a Buy on the Dip? (Motley Fool)
Apr-21-25 06:00PM	Coupang, Inc. (CPNG) Stock Moves -1.22%: What You Should Know (Zacks)
01:13PM	Coupang, Inc. (CPNG): A Bull Case Theory (Insider Monkey)
Apr-20-25 09:15AM	5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years (Motley Fool)
Apr-19-25 04:25AM	Is It Too Late to Buy Coupang Stock? (Motley Fool)
Apr-16-25 07:00AM	Dodge & Cox Emerging Markets Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-15-25 03:12AM	2 Top Tech Stocks That Could Make You a Millionaire (Motley Fool)
Apr-14-25 06:00PM	Coupang, Inc. (CPNG) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Apr-13-25 11:50PM	ClearBridge International Growth ACWI Ex-U.S. Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-12-25 03:30AM	As The South Korean Market Crumbles, Coupang Is Worth Watching (Seeking Alpha)
Apr-11-25 09:00AM	Here is What to Know Beyond Why Coupang, Inc. (CPNG) is a Trending Stock (Zacks)
Apr-09-25 11:40AM	BABA vs. CPNG: Which Stock Is the Better Value Option? (Zacks) +10.19%
05:40AM	Stock Market Sell-Off: The 3 Best Stocks to Buy Right Now (Motley Fool)
Apr-08-25 06:00PM	Coupang, Inc. (CPNG) Rises As Market Takes a Dip: Key Facts (Zacks)
Apr-07-25 07:00AM	27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks (Motley Fool)
Apr-06-25 12:45PM	2 Growth Stocks That Could Go Parabolic (Motley Fool)
Apr-04-25 03:02PM	Why Coupang Stock Plummeted Today (Motley Fool) -6.52%
Apr-03-25 12:01AM	EXCLUSIVE: Farfetch Reboots Under Coupang, With a Focus on Customers and the Marketplace (WWD)
Apr-02-25 06:00PM	Coupang, Inc. (CPNG) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-31-25 09:00AM	Is Trending Stock Coupang, Inc. (CPNG) a Buy Now? (Zacks)
Mar-30-25 07:45AM	Prediction: These 2 Stocks Will Be Worth More Than Strategy 2 Years From Now (Motley Fool)
Mar-29-25 08:07AM	3 Magnificent Growth Stocks to Buy Hand Over Fist With $500 (Motley Fool)
Mar-27-25 06:00PM	Coupang, Inc. (CPNG) Stock Moves -0.25%: What You Should Know (Zacks)
Mar-22-25 03:24PM	Is Coupang, Inc. (CPNG) the Top Stock to Buy According to Durable Capital Partners? (InsiderMonkey)
Mar-21-25 05:50PM	Coupang, Inc. (CPNG) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:25AM	Nasdaq Correction: 2 Winning Stocks on Sale Right Now (Motley Fool)
Mar-20-25 06:00PM	Coupang, Inc. (CPNG) Dips More Than Broader Market: What You Should Know (Zacks)
Mar-19-25 07:00AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Fool)
Mar-18-25 09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:30AM	Coupang Named a Fast Company Most Innovative Company for 2025 (Business Wire)
03:08AM	Is Coupang (CPNG) One of the Best High Growth Stocks? (Insider Monkey)
Mar-16-25 04:35AM	2 No-Brainer Hypergrowth Stocks to Buy During This Nasdaq Market Correction (Motley Fool)
Mar-12-25 05:50PM	Coupang, Inc. (CPNG) Outperforms Broader Market: What You Need to Know (Zacks)
Mar-06-25 07:30AM	The Best Stocks to Invest $50,000 in Right Now (Motley Fool)
Mar-04-25 11:14PM	Coupang, Inc. (CPNG): Among the Best Stocks To Invest In According to Billionaires (Insider Monkey)
05:35PM	How to Play This Wall Street Melt Down (InvestorPlace)
09:00AM	Coupang, Inc. (CPNG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SVF Investments (UK) Ltd	10% Owner	Jun 13 '25	Sale	28.25	10,000,000	282,500,000	309,542,259	Jun 17 09:00 PM
SVF Investments (UK) Ltd	Shareholder	Jun 13 '25	Proposed Sale	28.31	10,000,000	283,100,000		Jun 13 09:00 PM
Anand Gaurav	Chief Financial Officer	May 29 '25	Sale	28.11	175,000	4,919,635	2,092,290	Jun 02 04:21 PM
Sun Benjamin	Director	May 28 '25	Sale	28.36	200,000	5,671,560	1,319,421	May 30 04:39 PM
Gaurav Anand	affiliate	May 29 '25	Proposed Sale	28.11	175,000	4,919,627		May 29 06:12 PM
Benjamin Sun	Affiliate	May 28 '25	Proposed Sale	28.33	200,000	5,665,552		May 28 04:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 14 '25	Buy	26.78	750,000	20,082,300	54,481,161	May 16 07:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 15 '25	Buy	26.86	650,000	17,458,610	55,131,161	May 16 07:30 PM
Anand Gaurav	Chief Financial Officer	May 12 '25	Sale	26.10	75,350	1,966,921	2,267,290	May 14 04:21 PM
SVF Investments (UK) Ltd	10% Owner	May 08 '25	Sale	25.75	30,000,000	772,500,000	319,542,259	May 12 09:00 PM
GAURAV ANAND	Officer	May 12 '25	Proposed Sale	26.00	75,350	1,959,100		May 12 04:23 PM
Sun Benjamin	Director	May 08 '25	Sale	26.03	200,000	5,206,120	1,519,421	May 12 04:15 PM
Kang Hanseung	Rep Director, Business Mngmt	May 08 '25	Sale	26.17	69,931	1,830,248	599,841	May 12 04:14 PM
Lee Jonathan D.	Chief Accounting Officer	May 08 '25	Sale	26.17	8,105	212,126	124,775	May 12 04:12 PM
Kolari Pranam	VP, Search and Recommendations	May 08 '25	Sale	26.17	6,777	177,385	170,329	May 12 04:10 PM
SVF Investments (UK) Ltd	Shareholder	May 08 '25	Proposed Sale	26.60	30,000,000	798,000,000		May 08 09:00 PM
Pranam Kolari	affiliate	May 08 '25	Proposed Sale	26.17	6,777	177,385		May 08 04:35 PM
Benjamin Sun	Affiliate	May 08 '25	Proposed Sale	26.00	200,000	5,199,322		May 08 04:29 PM
Han Seung Kang	affiliate	May 08 '25	Proposed Sale	26.17	69,931	1,830,247		May 08 04:29 PM
Jonathan Lee	affiliate	May 08 '25	Proposed Sale	26.17	8,105	212,127		May 08 04:22 PM
Kolari Pranam	VP, Search and Recommendations	May 02 '25	Sale	23.85	9,347	222,926	177,106	May 02 09:16 PM
Pranam Kolari	affiliate	May 02 '25	Proposed Sale	23.47	9,347	219,374		May 02 08:34 PM
Kolari Pranam	VP, Search and Recommendations	Apr 02 '25	Sale	21.94	675	14,810	186,453	Apr 03 04:24 PM
Pranam Kolari	affiliate	Apr 02 '25	Proposed Sale	22.18	675	14,972		Apr 02 06:52 PM
Sun Benjamin	Director	Mar 17 '25	Sale	23.43	250,000	5,856,853	1,719,421	Mar 19 09:06 PM
Kang Hanseung	Rep Director, Business Mngmt	Mar 17 '25	Sale	23.00	40,000	920,000	669,772	Mar 19 04:23 PM
Han Seung Kang	affiliate	Mar 17 '25	Proposed Sale	22.51	40,000	900,400		Mar 17 05:01 PM
Benjamin Sun	Affiliate	Mar 17 '25	Proposed Sale	23.40	250,000	5,849,185		Mar 17 04:39 PM
Anand Gaurav	Chief Financial Officer	Mar 10 '25	Sale	22.03	75,350	1,660,262	2,342,640	Mar 11 04:27 PM
GAURAV ANAND	Officer	Mar 10 '25	Proposed Sale	22.75	75,350	1,714,212		Mar 10 04:24 PM
Rogers Harold	See Remarks	Mar 05 '25	Sale	23.50	273,977	6,437,473	514,324	Mar 07 04:24 PM
Harold Rogers	affiliate	Mar 05 '25	Proposed Sale	23.36	273,977	6,400,103		Mar 05 04:36 PM
Kolari Pranam	VP, Search and Recommendations	Feb 27 '25	Sale	24.76	7,172	177,579	129,634	Feb 28 04:22 PM
Pranam Kolari	affiliate	Feb 27 '25	Proposed Sale	25.01	7,172	179,372		Feb 27 04:28 PM
Kolari Pranam	VP, Search and Recommendations	Feb 03 '25	Sale	22.98	8,459	194,388	136,806	Feb 04 04:23 PM
Pranam Kolari	affiliate	Feb 03 '25	Proposed Sale	23.51	8,459	198,871		Feb 03 04:22 PM
Kolari Pranam	VP, Search and Recommendations	Jan 02 '25	Sale	22.10	775	17,128	145,265	Jan 02 08:33 PM
Pranam Kolari	affiliate	Jan 02 '25	Proposed Sale	21.98	775	17,035		Jan 02 07:20 PM
Kim Bom	CEO and Chairman	Nov 11 '24	Sale	22.97	15,000,000	344,550,000	2,000,000	Nov 13 06:16 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Nov 08 '24	Buy	24.01	750,000	18,009,975	52,038,723	Nov 12 09:15 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Nov 11 '24	Buy	24.08	687,700	16,557,409	52,726,423	Nov 12 09:15 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Nov 07 '24	Buy	24.77	612,499	15,172,703	51,288,723	Nov 12 09:15 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Nov 12 '24	Buy	24.46	200,000	4,891,940	52,926,423	Nov 12 09:15 PM
Bom Kim	Officer	Nov 11 '24	Proposed Sale	24.10	15,000,000	361,500,000		Nov 12 09:08 AM
Kolari Pranam	VP, Search and Recommendations	Nov 07 '24	Sale	24.27	5,494	133,339	146,040	Nov 08 04:38 PM
Pranam Kolari	affiliate	Nov 07 '24	Proposed Sale	26.89	5,494	147,734		Nov 07 06:13 PM
Kolari Pranam	VP, Search and Recommendations	Nov 04 '24	Sale	25.36	11,631	294,962	151,534	Nov 06 04:31 PM
Pranam Kolari	affiliate	Nov 04 '24	Proposed Sale	25.40	11,631	295,427		Nov 04 04:09 PM
Kolari Pranam	See Remarks	Oct 02 '24	Sale	24.23	956	23,164	163,165	Oct 04 04:22 PM
Pranam Kolari	affiliate	Oct 02 '24	Proposed Sale	24.23	956	23,164		Oct 02 05:07 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 22 '24	Buy	22.93	200,000	4,586,340	50,676,224	Aug 23 09:00 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 21 '24	Buy	22.95	100,000	2,294,980	50,476,224	Aug 23 09:00 PM
Sun Benjamin	Director	Aug 19 '24	Sale	23.36	200,000	4,672,000	1,969,421	Aug 21 07:21 PM
Sun Brothers LLC	Benjamin Sun, Managing Member,	Aug 19 '24	Proposed Sale	23.36	200,000	4,672,424		Aug 19 05:12 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 13 '24	Buy	22.58	251,300	5,675,609	50,126,224	Aug 15 08:37 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 14 '24	Buy	22.15	150,000	3,322,500	50,276,224	Aug 15 08:37 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 15 '24	Buy	22.39	100,000	2,239,100	50,376,224	Aug 15 08:37 PM
Kolari Pranam	See Remarks	Aug 14 '24	Sale	22.63	6,235	141,098	164,121	Aug 15 04:59 PM
Anand Gaurav	Chief Financial Officer	Aug 13 '24	Sale	22.75	200,000	4,550,000	1,937,500	Aug 14 04:56 PM
Pranam Kolari	affiliate	Aug 02 '24	Proposed Sale	22.63	6,235	141,098		Aug 14 04:21 PM
Anand Gaurav	affiliate	Aug 13 '24	Proposed Sale	22.75	200,000	4,550,261		Aug 13 03:36 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 08 '24	Buy	22.29	800,000	17,831,001	49,724,924	Aug 12 09:13 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Aug 09 '24	Buy	22.64	150,000	3,396,300	49,874,924	Aug 12 09:13 PM
Kolari Pranam	See Remarks	Aug 02 '24	Sale	19.90	10,432	207,597	170,356	Aug 05 04:30 PM
Pranam Kolari	affiliate	Aug 02 '24	Proposed Sale	19.90	10,432	207,597		Aug 02 04:29 PM

Dollar change +0.02
Percentage change 0.18	%

ROIV Roivant Sciences Ltd daily Stock Chart

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: VTI IJH VB XBI VXF VBK MDY IBB IJK SPMD

Index	-	P/E	-	EPS (ttm)	-0.25	Insider Own	39.03%	Shs Outstand	695.94M	Perf Week	-5.26%
Market Cap	7.47B	Forward P/E	-	EPS next Y	-1.33	Insider Trans	-2.10%	Shs Float	414.48M	Perf Month	-2.27%
Enterprise Value	3.18B	PEG	-	EPS next Q	-0.25	Inst Own	65.73%	Short Float	10.87%	Perf Quarter	9.03%
Income	-171.98M	P/S	98.06	EPS this Y	-397.39%	Inst Trans	-1.34%	Short Ratio	6.80	Perf Half Y	-3.85%
Sales	76.19M	P/B	1.63	EPS next Y	-11.56%	ROA	-7.20%	Short Interest	45.06M	Perf YTD	-7.10%
Book/sh	6.74	P/C	1.53	EPS next 5Y	-	ROE	-8.56%	52W High	13.06 -15.82%	Perf Year	1.48%
Cash/sh	7.19	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-3.60%	52W Low	8.73 25.89%	Perf 3Y	133.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	96.95%	Volatility	2.31% 2.92%	Perf 5Y	-
Dividend TTM	-	EV/Sales	41.76	EPS Y/Y TTM	-104.46%	Oper. Margin	-1485.18%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	33.47	Sales Y/Y TTM	-38.94%	Profit Margin	-225.71%	RSI (14)	44.75	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	33.47	EPS Q/Q	-55.10%	SMA20	-2.58%	Beta	1.15	Target Price	16.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-73.83%	SMA50	-1.32%	Rel Volume	0.50	Prev Close	10.97
Employees	750	LT Debt/Eq	0.02	Earnings	May 29 BMO	SMA200	-1.89%	Avg Volume	6.63M	Price	10.99
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.06% -86.00%	Trades		Volume	3,307,159	Change	0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
02:17PM	Loading…
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
12:13PM	Loading…
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
04:32PM	Loading…
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
May-07-24 02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)
Feb-13-24 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update (GlobeNewswire)
Feb-10-24 02:55AM	Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares (GuruFocus.com)
Jan-30-24 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 (GlobeNewswire)
Dec-27-23 08:05PM	5 High Growth International Stocks to Buy (Insider Monkey)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -7.78% +5.82%
Dec-14-23 09:00AM	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
02:38AM	5 Stocks Under $20 To Buy Now (Insider Monkey)
Nov-27-23 08:00AM	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus (GlobeNewswire)
Nov-14-23 01:00PM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update (GlobeNewswire)
Nov-10-23 08:00AM	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors (GlobeNewswire)
Oct-30-23 05:30PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	This $5 Billion Biotech Home Run Took Less Than a Year (The Wall Street Journal)
Oct-23-23 03:02PM	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion (Investopedia) -11.02%
10:31AM	Why Is Roivant Sciences (ROIV) Stock Up Today? (InvestorPlace)
09:52AM	Roche acquires Telavant, rights to bowel disease drug (Yahoo Finance Video)
06:55AM	Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion (The Wall Street Journal)
03:49AM	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal (The Wall Street Journal)
01:00AM	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant (GlobeNewswire)
Oct-13-23 08:00AM	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer (GlobeNewswire)
Oct-05-23 05:01AM	Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com) +5.04%
Oct-03-23 07:00AM	Vivek Ramaswamys Former Company Is Doing Just Fine Without Him (The Wall Street Journal)
Sep-30-23 05:00AM	Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com)
Sep-26-23 06:00AM	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire) +21.55%
Sep-11-23 08:00AM	Roivant Announces Completion of Redemption of its Outstanding Warrants (GlobeNewswire) -8.65%
Sep-09-23 10:51AM	The Brash Strategy That Made Vivek Ramaswamy a Fortune (The Wall Street Journal)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Sale	11.45	565,266	6,472,296	37,861,115	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Proposed Sale	11.46	577,007	6,611,850		Jun 20 04:35 PM
Venker Eric	Officer	Jun 20 '25	Proposed Sale	11.45	100,000	1,145,268		Jun 20 04:13 PM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Proposed Sale	11.45	565,266	6,472,996		Jun 18 04:38 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Sale	11.34	547,430	6,207,856	38,627,181	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Sale	11.19	200,800	2,246,952	38,426,381	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Proposed Sale	11.19	200,800	2,246,311		Jun 06 04:33 PM
Venker Eric	President & COO	Jun 03 '25	Option Exercise	3.85	785,026	3,022,350	2,028,501	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Option Exercise	3.85	600,000	2,310,000	1,677,197	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 03 '25	Sale	11.22	566,278	6,353,639	1,462,223	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Sale	11.07	433,722	4,801,303	1,243,475	Jun 04 09:00 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Proposed Sale	11.34	547,430	6,208,008		Jun 04 04:42 PM
ERIC VENKER	Officer	Jun 03 '25	Proposed Sale	11.22	566,278	6,355,961		Jun 03 05:14 PM
ERIC VENKER	Officer	Jun 02 '25	Proposed Sale	11.07	433,722	4,803,341		Jun 02 04:16 PM
Venker Eric	President & COO	May 20 '25	Option Exercise	3.85	100,000	385,000	1,177,197	May 22 09:00 PM
Venker Eric	President & COO	May 20 '25	Sale	10.95	100,000	1,095,000	1,077,197	May 22 09:00 PM
Venker Eric	Officer	May 20 '25	Proposed Sale	10.95	100,000	1,094,986		May 20 04:30 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Sale	11.18	625,000	6,987,500	39,174,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Sale	11.47	273,959	3,142,310	39,799,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Proposed Sale	11.18	625,000	6,987,388		May 07 04:37 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Proposed Sale	11.47	273,959	3,143,287		May 06 04:21 PM
Venker Eric	President & COO	Apr 21 '25	Option Exercise	3.85	100,000	385,000	1,216,345	Apr 22 09:00 PM
Venker Eric	President & COO	Apr 21 '25	Sale	10.22	100,000	1,022,000	1,116,345	Apr 22 09:00 PM
Venker Eric	Officer	Apr 21 '25	Proposed Sale	10.22	100,000	1,022,374		Apr 21 03:22 PM
Venker Eric	President & COO	Mar 24 '25	Option Exercise	3.85	602,311	2,318,897	1,561,768	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Option Exercise	3.85	400,000	1,540,000	1,274,979	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 24 '25	Sale	10.82	434,478	4,701,052	1,127,290	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Sale	11.06	315,522	3,489,673	959,457	Mar 24 09:21 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	10.95	650,000	7,117,500		Mar 20 05:27 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	11.11	100,000	1,110,537		Mar 20 03:54 PM
Venker Eric	President & COO	Feb 20 '25	Option Exercise	3.85	100,000	385,000	996,869	Feb 24 09:00 PM
Venker Eric	President & COO	Feb 20 '25	Sale	10.65	100,000	1,065,000	896,869	Feb 24 09:00 PM
Venker Eric	Officer	Feb 20 '25	Proposed Sale	10.65	100,000	1,065,022		Feb 20 03:35 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Option Exercise	3.85	187,500	721,875	390,764	Feb 18 09:00 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Sale	10.43	227,500	2,372,825	163,264	Feb 18 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Option Exercise	3.85	300,000	1,155,000	1,032,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Option Exercise	3.85	300,000	1,155,000	1,114,910	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Sale	10.53	217,384	2,289,054	732,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Sale	10.42	218,041	2,271,987	896,869	Feb 14 09:00 PM
Kumar Rakhi	Officer	Feb 13 '25	Proposed Sale	10.43	227,500	2,372,966		Feb 13 05:14 PM
Venker Eric	Officer	Feb 12 '25	Proposed Sale	10.50	600,000	6,300,000		Feb 12 05:29 PM
Venker Eric	President & COO	Jan 21 '25	Option Exercise	3.85	100,000	385,000	832,294	Jan 22 09:04 PM
Venker Eric	President & COO	Jan 21 '25	Sale	11.28	100,000	1,128,000	732,294	Jan 22 09:04 PM
Venker Eric	Officer	Jan 21 '25	Proposed Sale	11.28	100,000	1,128,457		Jan 21 04:30 PM
Roivant Sciences Ltd.	Director	Jan 13 '25	Buy	20.00	16,845,010	336,900,200	96,650,341	Jan 15 04:36 PM
Venker Eric	President & COO	Dec 27 '24	Option Exercise	3.85	250,000	962,500	845,580	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Option Exercise	3.85	250,000	962,500	918,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 27 '24	Sale	11.82	176,900	2,090,958	668,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Sale	11.54	177,704	2,050,704	740,976	Dec 31 09:00 PM
Venker Eric	Officer	Dec 27 '24	Proposed Sale	11.75	360,000	4,230,000		Dec 27 04:54 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 26 '24	Option Exercise	3.85	689,495	2,654,556	19,526,042	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 24 '24	Option Exercise	3.85	185,946	715,892	19,022,493	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 23 '24	Option Exercise	3.85	10,796	41,565	18,847,343	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 26 '24	Sale	12.01	689,495	8,280,835	18,836,547	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 24 '24	Sale	12.00	185,946	2,231,352	18,836,547	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 23 '24	Sale	12.00	10,796	129,552	18,836,547	Dec 26 09:00 PM
Venker Eric	President & COO	Dec 20 '24	Option Exercise	3.85	100,000	385,000	695,580	Dec 26 09:00 PM
Venker Eric	President & COO	Dec 20 '24	Sale	11.49	100,000	1,149,000	595,580	Dec 26 09:00 PM
Sukhatme Mayukh	Officer	Dec 26 '24	Proposed Sale	12.01	689,495	8,277,401		Dec 26 04:14 PM
Sukhatme Mayukh	Officer	Dec 24 '24	Proposed Sale	12.00	185,946	2,231,700		Dec 26 08:02 AM
Sukhatme Mayukh	Officer	Dec 23 '24	Proposed Sale	12.00	10,796	129,555		Dec 23 04:21 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 18 '24	Option Exercise	3.85	412,584	1,588,448	19,249,131	Dec 20 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 18 '24	Sale	12.05	412,584	4,971,637	18,836,547	Dec 20 09:00 PM
Venker Eric	Officer	Nov 20 '24	Proposed Sale	11.49	100,000	1,148,554		Dec 20 04:29 PM
Sukhatme Mayukh	Officer	Dec 18 '24	Proposed Sale	12.05	412,584	4,969,631		Dec 18 04:33 PM
Venker Eric	President & COO	Nov 20 '24	Option Exercise	3.85	100,000	385,000	706,525	Nov 22 09:00 PM
Venker Eric	President & COO	Nov 20 '24	Sale	11.32	100,000	1,132,000	606,525	Nov 22 09:00 PM
Venker Eric	Officer	Nov 20 '24	Proposed Sale	11.32	100,000	1,132,008		Nov 20 04:45 PM
Venker Eric	President & COO	Oct 21 '24	Option Exercise	3.85	100,000	385,000	717,470	Oct 22 09:00 PM
Venker Eric	President & COO	Oct 21 '24	Sale	11.65	100,000	1,165,000	617,470	Oct 22 09:00 PM
Venker Eric	Officer	Oct 21 '24	Proposed Sale	11.65	100,000	1,165,393		Oct 21 04:45 PM
QVT Financial LP	Director by Deputization	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 09:22 PM
QVT Financial LP	Director by Deputization	Sep 25 '24	Sale	11.77	50,000	588,500	23,055,358	Sep 26 09:22 PM
MANCHESTER KEITH S	Director	Sep 24 '24	Sale	11.62	368,052	4,278,604	1,412,126	Sep 26 08:35 PM
MANCHESTER KEITH S	Director	Sep 25 '24	Sale	11.77	134,948	1,587,704	1,277,178	Sep 26 08:35 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	1,565,670	18,200,914	5,723,423	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	991,593	11,666,389	4,731,830	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	577,186	6,709,787	2,079,059	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	415,551	4,889,317	1,713,508	Sep 26 08:34 PM
BNEI ZAHAV LLC	Director	Sep 25 '24	Proposed Sale	11.76	23,917	281,264		Sep 25 04:30 PM
RIOJA DOLCE LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:25 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 25 '24	Proposed Sale	11.76	134,948	1,586,988		Sep 25 04:23 PM
RIOJA LIETO LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:20 PM
DANIEL GOLD & LAURA GOLD	Director	Sep 25 '24	Proposed Sale	11.76	991,593	11,661,134		Sep 25 04:19 PM
Gline Matthew	CEO	Sep 23 '24	Option Exercise	3.85	1,550,000	5,967,500	19,853,800	Sep 24 09:01 PM
Gline Matthew	CEO	Sep 23 '24	Sale	11.79	1,983,257	23,382,600	17,870,543	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Option Exercise	3.85	250,000	962,500	459,322	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Sale	11.89	250,000	2,972,500	209,322	Sep 24 09:01 PM
DANIEL GOLD &LAURA GOLD JT TEN	Director	Sep 24 '24	Proposed Sale	11.62	1,565,670	18,200,914		Sep 24 07:53 PM
RIOJA LIETO LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:52 PM
RIOJA DOLCE LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:51 PM
BNEI ZAHAV LLC	Director	Sep 24 '24	Proposed Sale	11.62	37,762	438,983		Sep 24 07:48 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 24 '24	Proposed Sale	11.63	368,052	4,281,550		Sep 24 07:43 PM
Gline Matthew	Officer	Sep 23 '24	Proposed Sale	11.79	1,983,257	23,383,088		Sep 23 04:53 PM
Kumar Rakhi	Officer	Sep 23 '24	Proposed Sale	11.89	250,000	2,972,360		Sep 23 04:47 PM

CPNG

Coupang Inc

ROIV

Roivant Sciences Ltd

Upgrade your FINVIZ experience